Atrial fibrillation

Khachatryan, A., Doobaree, I. U., Spentzouris, G., Gusto, G., Zawaneh, Y., Mughal, F., et al. (2022). Direct Oral Anticoagulant (DOAC) Dosing in Patients with Non-valvular Atrial Fibrillation (NVAF) in the United Kingdom: A Retrospective Cohort Study Using CPRD Gold Database. Adv Ther. http://doi.org/10.1007/s12325-022-02368-y
van den Dries, C. J., Pajouheshnia, R., van den Ham, H. A., Souverein, P., Moons, K. G. M., Hoes, A. W., et al. (2022). Safety of off-label dose reduction of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Br J Clin Pharmacol. http://doi.org/10.1111/bcp.15534
Chung, S. C., O'Brien, B., Lip, G. Y. H., Fields, K. G., Muehlschlegel, J. D., Thakur, A., et al. (2022). Prognostic model for atrial fibrillation after cardiac surgery: a UK cohort study. Clin Res Cardiol. http://doi.org/10.1007/s00392-022-02068-1
Wu, J., Nadarajah, R., Nakao, Y. M., Nakao, K., Wilkinson, C., Mamas, M. A., et al. (2022). Temporal trends and patterns in atrial fibrillation incidence: A population-based study of 3·4 million individuals. Lancet Reg Health Eur, 17, 100386. http://doi.org/10.1016/j.lanepe.2022.100386